Amittha Wickrema

Biosciences Graduate Program Association
  1. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. Elife. 2022 08 30; 11. View in: PubMed

  2. PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation. Blood Cancer Discov. 2022 09 06; 3(5):444-467. View in: PubMed

  3. BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines. Haematologica. 2021 12 01; 106(12):3223-3227. View in: PubMed

  4. Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107. View in: PubMed

  5. Epigenetic modifiers in normal and aberrent erythropoeisis. Semin Hematol. 2021 01; 58(1):15-26. View in: PubMed

  6. The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. Am J Transplant. 2021 04; 21(4):1365-1375. View in: PubMed

  7. HIF-1 directly induces TET3 expression to enhance 5-hmC density and induce erythroid gene expression in hypoxia. Blood Adv. 2020 07 14; 4(13):3053-3062. View in: PubMed

  8. Heterogeneity of Red Blood Cells: Causes and Consequences. Front Physiol. 2020; 11:392. View in: PubMed

  9. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv. 2019 12 10; 3(23):3962-3967. View in: PubMed

  10. Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks. Clin Cancer Res. 2019 09 15; 25(18):5638-5649. View in: PubMed

  11. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discov. 2019 06; 9(6):778-795. View in: PubMed

  12. Disruption of erythroid nuclear opening and histone release in myelodysplastic syndromes. Cancer Med. 2019 03; 8(3):1169-1174. View in: PubMed

  13. Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity. Blood Adv. 2018 12 11; 2(23):3540-3552. View in: PubMed

  14. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018 12 03; 128(12):5479-5488. View in: PubMed

  15. Expression of functional folate receptors in multiple myeloma. Leuk Lymphoma. 2018 12; 59(12):2982-2989. View in: PubMed

  16. Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype. Oncotarget. 2018 Feb 09; 9(11):9728-9740. View in: PubMed

  17. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004. View in: PubMed

  18. Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/?-Catenin Activation. Cancer Res. 2017 09 15; 77(18):4846-4857. View in: PubMed

  19. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest. 2017 Apr 03; 127(4):1316-1320. View in: PubMed

  20. Utilization of leukapheresis and CD4 positive selection in Treg isolation and the ex-vivo expansion for a clinical application in transplantation and autoimmune disorders. Oncotarget. 2016 Nov 29; 7(48):79474-79484. View in: PubMed

  21. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica. 2016 11; 101(11):1426-1433. View in: PubMed

  22. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103. View in: PubMed

  23. Nuclear Condensation during Mouse Erythropoiesis Requires Caspase-3-Mediated Nuclear Opening. Dev Cell. 2016 Mar 07; 36(5):498-510. View in: PubMed

  24. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072. View in: PubMed

  25. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43. View in: PubMed

  26. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2015 Nov 17; 112(46):E6359-68. View in: PubMed

  27. Ineffective erythropoiesis caused by binucleated late-stage erythroblasts in mDia2 hematopoietic specific knockout mice. Haematologica. 2016 Jan; 101(1):e1-5. View in: PubMed

  28. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34. View in: PubMed

  29. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015 May 14; 125(20):3144-52. View in: PubMed

  30. Unexplained anaemia in the elderly is characterised by features of low grade inflammation. Br J Haematol. 2014 Oct; 167(2):286-9. View in: PubMed

  31. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73. View in: PubMed

  32. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep. 2014 Jan 16; 6(1):231-244. View in: PubMed

  33. Tropomodulin3-null mice are embryonic lethal with anemia due to impaired erythroid terminal differentiation in the fetal liver. Blood. 2014 Jan 30; 123(5):758-67. View in: PubMed

  34. Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem. 2013 Aug 16; 288(33):23814-22. View in: PubMed

  35. High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis. J Biol Chem. 2013 Mar 29; 288(13):8805-14. View in: PubMed

  36. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9. View in: PubMed

  37. Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine. 2013 Jan; 61(1):329-35. View in: PubMed

  38. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9. View in: PubMed

  39. NF-Y recruits both transcription activator and repressor to modulate tissue- and developmental stage-specific expression of human ?-globin gene. PLoS One. 2012; 7(10):e47175. View in: PubMed

  40. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15. View in: PubMed

  41. A novel role for survivin in erythroblast enucleation. Haematologica. 2012 Oct; 97(10):1471-9. View in: PubMed

  42. Erythroblast enucleation. Stem Cells Int. 2011; 2011:139851. View in: PubMed

  43. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45. View in: PubMed

  44. Will cord blood stem cells come to the rescue of keratinocyte growth factor? Leuk Lymphoma. 2011 Aug; 52(8):1423-4. View in: PubMed

  45. P. falciparum modulates erythroblast cell gene expression in signaling and erythrocyte production pathways. PLoS One. 2011 May 04; 6(5):e19307. View in: PubMed

  46. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem. 2011 Jul 15; 286(28):25211-23. View in: PubMed

  47. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011 Feb 01; 71(3):955-63. View in: PubMed

  48. Vesicle trafficking plays a novel role in erythroblast enucleation. Blood. 2010 Oct 28; 116(17):3331-40. View in: PubMed

  49. Analysis of the kinetics of band 3 diffusion in human erythroblasts during assembly of the erythrocyte membrane skeleton. Br J Haematol. 2010 Sep; 150(5):592-600. View in: PubMed

  50. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma. 2009 Nov; 50(11):1865-71. View in: PubMed

  51. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1394-9. View in: PubMed

  52. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17. View in: PubMed

  53. Coupled transcription-splicing regulation of mutually exclusive splicing events at the 5' exons of protein 4.1R gene. Blood. 2009 Nov 05; 114(19):4233-42. View in: PubMed

  54. Stage-specific susceptibility of human erythroblasts to Plasmodium falciparum malaria infection. Blood. 2009 Oct 22; 114(17):3652-5. View in: PubMed

  55. High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma. Biochem Biophys Res Commun. 2009 Jul 24; 385(2):160-4. View in: PubMed

  56. Loss of specific chaperones involved in membrane glycoprotein biosynthesis during the maturation of human erythroid progenitor cells. J Biol Chem. 2009 May 22; 284(21):14547-57. View in: PubMed

  57. Activation of protein kinase C{eta} by type I interferons. J Biol Chem. 2009 Apr 17; 284(16):10301-14. View in: PubMed

  58. Alternative pre-mRNA splicing switches modulate gene expression in late erythropoiesis. Blood. 2009 Apr 02; 113(14):3363-70. View in: PubMed

  59. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16. View in: PubMed

  60. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma. 2008 Oct; 49(10):1945-53. View in: PubMed

  61. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008 Oct 15; 112(8):3434-43. View in: PubMed

  62. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7. View in: PubMed

  63. Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts. J Biol Chem. 2008 Mar 14; 283(11):6997-7006. View in: PubMed

  64. Erythroid and megakaryocytic transformation. Oncogene. 2007 Oct 15; 26(47):6803-15. View in: PubMed

  65. Stable transcriptional status in the apoptotic erythroid genome. Biochem Biophys Res Commun. 2007 Aug 03; 359(3):556-62. View in: PubMed

  66. Friend of GATA-1-independent transcriptional repression: a novel mode of GATA-1 function. Blood. 2007 Jun 15; 109(12):5230-3. View in: PubMed

  67. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A. 2005 Aug 09; 102(32):11480-5. View in: PubMed

  68. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38. View in: PubMed

  69. Tetrodotoxin-sensitive Na+ channels and muscarinic and purinergic receptors identified in human erythroid progenitor cells and red blood cell ghosts. Proc Natl Acad Sci U S A. 2004 Aug 17; 101(33):12370-4. View in: PubMed

  70. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004 Jun; 10(6):386-94. View in: PubMed

  71. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci U S A. 2004 Jan 06; 101(1):147-52. View in: PubMed

  72. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6. View in: PubMed

  73. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13. View in: PubMed

  74. The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells. Proc Natl Acad Sci U S A. 2003 Jun 10; 100(12):7366-71. View in: PubMed

  75. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant. 2003 May; 31(9):813-6. View in: PubMed

  76. Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood. 2003 Jan 15; 101(2):524-31. View in: PubMed

  77. Na pump isoforms in human erythroid progenitor cells and mature erythrocytes. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14572-7. View in: PubMed

  78. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun. 2002 Oct 04; 297(4):760-4. View in: PubMed

  79. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol. 2002 Jun 15; 168(12):5984-8. View in: PubMed

  80. Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene. 2002 Feb 28; 21(10):1556-62. View in: PubMed

  81. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem. 2002 Mar 08; 277(10):7726-35. View in: PubMed

  82. Role of JunB in erythroid differentiation. J Biol Chem. 2002 Feb 15; 277(7):4859-66. View in: PubMed

  83. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant. 2001 Sep; 28(6):557-62. View in: PubMed

  84. Phosphatase inhibition promotes antiapoptotic but not proliferative signaling pathways in erythropoietin-dependent HCD57 cells. Blood. 2000 Sep 15; 96(6):2084-92. View in: PubMed

  85. Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors. Biochem Biophys Res Commun. 2000 Aug 18; 275(1):16-9. View in: PubMed

  86. Interferon gamma delays apoptosis of mature erythroid progenitor cells in the absence of erythropoietin. Blood. 2000 Jun 15; 95(12):3742-9. View in: PubMed

  87. Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem. 1999 Aug 27; 274(35):24469-74. View in: PubMed

  88. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Exp Hematol. 1999 Aug; 27(8):1315-21. View in: PubMed

  89. Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol. 1999 Jul; 27(7):1124-32. View in: PubMed

  90. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood. 1999 Jun 01; 93(11):3757-73. View in: PubMed

  91. AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol Cell Biol. 1998 Jul; 18(7):3699-707. View in: PubMed

  92. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood. 1993 Oct 15; 82(8):2340-52. View in: PubMed

  93. Erythroid-specific processing of human beta spectrin I pre-mRNA. Blood. 1994 Sep 15; 84(6):1992-9. View in: PubMed

  94. Changes in cytoskeletal proteins and their mRNAs during maturation of human erythroid progenitor cells. J Cell Physiol. 1994 Sep; 160(3):417-26. View in: PubMed

  95. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood. 1995 Jul 01; 86(1):381-9. View in: PubMed

  96. Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest. 1994 Jul; 94(1):34-43. View in: PubMed

  97. Acyl-acyl-carrier protein: lysomonogalactosyldiacylglycerol acyltransferase from the cyanobacterium Anabaena variabilis. Biochim Biophys Acta. 1988 Dec 16; 963(3):493-500. View in: PubMed

  98. Abundance and stability of erythropoietin receptor mRNA in mouse erythroid progenitor cells. Blood. 1991 Nov 01; 78(9):2269-75. View in: PubMed

  99. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood. 1992 Oct 15; 80(8):1940-9. View in: PubMed